Share Price:

APNASPENAspen Pharmacare Hldgs21705-215 (-0.98%)
Our Response to Covid
Country Sites

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Year: 2023

Aspen concludes two significant agreements with Sandoz for China and Europe

Durban, South Africa – JSE-listed Aspen Pharmacare Holdings Limited, a global multinational specialty pharmaceutical company, has announced that Aspen Global Incorporated (“AGI”), its wholly owned subsidiary incorporated in Mauritius, has concluded two interdependent agreements with Sandoz AG (“Sandoz”) concerning the acquisition of Sandoz’s Chinese business and the disposal to Sandoz of four anaesthetic products in… Continue reading Aspen concludes two significant agreements with Sandoz for China and Europe

Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility

Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility Durban, South Africa – Aspen is pleased to announce further details on one of the contract manufacturing agreements mentioned in its recent announcement of financial results for the year ended 30 June 2023… Continue reading Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility

Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated

Stephen Saad, Aspen Group Chief Executive

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported a strong performance for the year ended 30 June 2023. SALIENT HIGHLIGHTS Revenue grew by 5% (-3% in constant exchange rate (“CER”)) to R40 709 million (FY2022: R38 606) Normalised EBITDA rose by 1% (-6% in CER) to R11… Continue reading Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated

Aspen and Lilly enter into agreement in South Africa and the rest of Sub-Saharan Africa

Stephen Saad, Aspen Group Chief Executive

Subject to approval from relevant Competition Authorities, Lilly will enter a strategic agreement with Aspen to continue serving patients and bring innovative therapies to South Africa and the rest of Sub-Saharan Africa. Johannesburg – In an effort to improve the reach and expand the access of its innovative portfolio of medicines to the patients who… Continue reading Aspen and Lilly enter into agreement in South Africa and the rest of Sub-Saharan Africa

H1 2024 Results Short Form Announcement

View or Download

Aspen hosts Mandela Day for 13th consecutive year, having reached 865 000 beneficiaries

Durban – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded pharmaceutical company, is participating in Mandela Day for the 13th consecutive year with more than 60 activities in 23 countries.   Stephen Saad, Aspen Group Chief Executive said, “Now, more than ever, communities globally are in desperate need of various… Continue reading Aspen hosts Mandela Day for 13th consecutive year, having reached 865 000 beneficiaries

Aspen, Saudi Chemical Company Holding and its subsidiary AJA Pharma enter into a memorandum of understanding.

Dubai, United Arab Emirates – Aspen Healthcare FZ LLC (“Aspen Healthcare”), a subsidiary of Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded multinational pharmaceutical company, has entered into a memorandum of understanding (“MOU”) with Saudi Chemical Company Holding (“SCCH”), a well-known company in the local market of the Kingdom of Saudi Arabia, and… Continue reading Aspen, Saudi Chemical Company Holding and its subsidiary AJA Pharma enter into a memorandum of understanding.

Aspen reports a creditable and resilient performance under challenging trading conditions

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported creditable unaudited interim Group financial results for the six months ended 31 December 2022.   Salient Highlights   Revenue decreased by 1% (-6% in constant exchange rate (“CER”)) to R19,2 billion (December 2021: R19,4 billion) Normalised EBITDA decreased by… Continue reading Aspen reports a creditable and resilient performance under challenging trading conditions

Our Purpose

Find out more
To improve the health and quality of life of patients.

Our Vision

Find out more
To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally.

Our Values

Find out more
Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group.
aspen-holdings-logo-white-img

Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912

Medical Careline (South Africa) 0800 118 088

Facebook-f Twitter-square Instagram Linkedin

About Aspen

We Care

Careers

Contact Us

ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600

Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.